PMID- 32609372
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20230315
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Print)
IS  - 0586-7614 (Linking)
VI  - 47
IP  - 1
DP  - 2021 Jan 23
TI  - Association Between Circulating Lipids and Future Weight Gain in Individuals With 
      an At-Risk Mental State and in First-Episode Psychosis.
PG  - 160-169
LID - 10.1093/schbul/sbaa087 [doi]
AB  - Patients with schizophrenia have a lower than average life span, largely due to 
      the increased prevalence of cardiometabolic comorbidities. There is an unmet 
      public health need to identify individuals with psychotic disorders who have a 
      high risk of rapid weight gain and who are at risk of developing metabolic 
      complications. Here, we applied mass spectrometry-based lipidomics in a 
      prospective study comprising 48 healthy controls (CTR), 44 first-episode 
      psychosis (FEP) patients, and 22 individuals at clinical high risk (CHR) for 
      psychosis, from 2 study centers (Turku, Finland and London, UK). Baseline serum 
      samples were analyzed using lipidomics, and body mass index (BMI) was assessed at 
      baseline and after 12 months. We found that baseline triacylglycerols (TGs) with 
      low double-bond counts and carbon numbers were positively associated with the 
      change in BMI at follow-up. In addition, a molecular signature comprised of 2 TGs 
      (TG[48:0] and TG[45:0]) was predictive of weight gain in individuals with a 
      psychotic disorder, with an area under the receiver operating characteristic 
      curve (AUROC) of 0.74 (95% CI: 0.60-0.85). When independently tested in the CHR 
      group, this molecular signature predicted said weight change with AUROC = 0.73 
      (95% CI: 0.61-0.83). We conclude that molecular lipids may serve as a predictor 
      of weight gain in psychotic disorders in at-risk individuals and may thus provide 
      a useful marker for identifying individuals who are most prone to developing 
      cardiometabolic comorbidities.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the 
      Maryland Psychiatric Research Center. All rights reserved. For permissions, 
      please email: journals.permissions@oup.com.
FAU - Lamichhane, Santosh
AU  - Lamichhane S
AD  - Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, 
      Finland.
FAU - Dickens, Alex M
AU  - Dickens AM
AD  - Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, 
      Finland.
FAU - Sen, Partho
AU  - Sen P
AD  - Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, 
      Finland.
FAU - Laurikainen, Heikki
AU  - Laurikainen H
AD  - Department of Psychiatry, University of Turku, Turku, Finland.
AD  - Turku PET Centre, Turku University Hospital, Turku, Finland.
FAU - Borgan, Faith
AU  - Borgan F
AD  - Department of Psychosis Studies, Institute of Psychiatry, Psychology & 
      Neuroscience, King's College London, London, UK.
AD  - Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith 
      Hospital, Imperial College London, London, UK.
FAU - Suvisaari, Jaana
AU  - Suvisaari J
AD  - Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
FAU - Hyotylainen, Tuulia
AU  - Hyotylainen T
AD  - Department of Chemistry, Orebro University, Orebro, Sweden.
FAU - Howes, Oliver
AU  - Howes O
AD  - Department of Psychosis Studies, Institute of Psychiatry, Psychology & 
      Neuroscience, King's College London, London, UK.
AD  - Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith 
      Hospital, Imperial College London, London, UK.
FAU - Hietala, Jarmo
AU  - Hietala J
AD  - Department of Psychiatry, University of Turku, Turku, Finland.
AD  - Turku PET Centre, Turku University Hospital, Turku, Finland.
FAU - Oresic, Matej
AU  - Oresic M
AD  - Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, 
      Finland.
AD  - School of Medical Sciences, Orebro University, Orebro, Sweden.
LA  - eng
GR  - MC_U120097115/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
RN  - 0 (Biomarkers)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Disease Susceptibility
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lipidomics
MH  - Male
MH  - Mass Spectrometry
MH  - Psychotic Disorders/*blood/*physiopathology
MH  - Risk
MH  - Schizophrenia/*blood/*physiopathology
MH  - Triglycerides/*blood
MH  - Weight Gain/*physiology
MH  - Young Adult
PMC - PMC7825089
OTO - NOTNLM
OT  - first-episode psychosis
OT  - lipidomics
OT  - metabolic co-morbidities
OT  - metabolomics
OT  - weight gain
EDAT- 2020/07/02 06:00
MHDA- 2021/11/20 06:00
PMCR- 2021/07/01
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2021/07/01 00:00 [pmc-release]
AID - 5865792 [pii]
AID - sbaa087 [pii]
AID - 10.1093/schbul/sbaa087 [doi]
PST - ppublish
SO  - Schizophr Bull. 2021 Jan 23;47(1):160-169. doi: 10.1093/schbul/sbaa087.